Go Pro
→ This looks like plywood. It's not. (From Eagle Publishing) (Ad)tc pixel Free LABT Stock Alerts

Lakewood-Amedex Biotherapeutics (LABT) Competitors

Lakewood-Amedex Biotherapeutics logo
$1.88 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern
Compare

LABT vs. TPST, BIVI, BCDA, APLT, and HIND

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? Lakewood-Amedex Biotherapeutics's main competitors and comparable companies include Tempest Therapeutics (TPST), BioVie (BIVI), BioCardia (BCDA), Applied Therapeutics (APLT), and Vyome (HIND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakewood-Amedex Biotherapeutics compare to Tempest Therapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

22.5% of Tempest Therapeutics shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 36.2% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lakewood-Amedex Biotherapeutics had 5 more articles in the media than Tempest Therapeutics. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Tempest Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.60 beat Tempest Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Positive
Tempest Therapeutics Neutral

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Tempest Therapeutics N/A -576.56%-134.99%

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
Tempest TherapeuticsN/AN/A-$26.26M-$4.28N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Lakewood-Amedex Biotherapeutics and Tempest Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to BioVie?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

BioVie is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
BioVieN/AN/A-$22.07M-$3.15N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 3 more articles in the media than BioVie. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 2 mentions for BioVie. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.60 beat BioVie's score of 0.25 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakewood-Amedex Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioVie
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioVie's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
BioVie N/A -126.02%-108.88%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioVie
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

4.6% of BioVie shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 0.9% of BioVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lakewood-Amedex Biotherapeutics beats BioVie on 7 of the 9 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to BioCardia?

BioCardia (NASDAQ:BCDA) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 2,214.81%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts clearly believe BioCardia is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$60K272.52-$8.23M-$0.64N/A
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
BioCardiaN/A -569.36% -183.15%
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 4 more articles in the media than BioCardia. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 1 mentions for BioCardia. BioCardia's average media sentiment score of 1.00 beat Lakewood-Amedex Biotherapeutics' score of 0.60 indicating that BioCardia is being referred to more favorably in the media.

Company Overall Sentiment
BioCardia Positive
Lakewood-Amedex Biotherapeutics Positive

Summary

BioCardia beats Lakewood-Amedex Biotherapeutics on 8 of the 13 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Applied Therapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

98.3% of Applied Therapeutics shares are held by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Applied Therapeutics N/A -340.84%-175.00%

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A

In the previous week, Lakewood-Amedex Biotherapeutics had 5 more articles in the media than Applied Therapeutics. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Applied Therapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.60 beat Applied Therapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Positive
Applied Therapeutics Neutral

Applied Therapeutics has a consensus price target of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Lakewood-Amedex Biotherapeutics beats Applied Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Vyome?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Vyome. Vyome is trading at a lower price-to-earnings ratio than Lakewood-Amedex Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/A-$3.85M-$4.75N/A
Vyome$320K48.70-$10.26M-$3.37N/A

Lakewood-Amedex Biotherapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Vyome's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Vyome -3,024.84%-197.33%-138.14%

22.1% of Vyome shares are owned by institutional investors. 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vyome has a consensus target price of $9.25, suggesting a potential upside of 316.67%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than Lakewood-Amedex Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakewood-Amedex Biotherapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Vyome
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Lakewood-Amedex Biotherapeutics had 2 more articles in the media than Vyome. MarketBeat recorded 5 mentions for Lakewood-Amedex Biotherapeutics and 3 mentions for Vyome. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.60 beat Vyome's score of 0.33 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakewood-Amedex Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vyome
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Lakewood-Amedex Biotherapeutics and Vyome tied by winning 7 of the 14 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABT vs. The Competition

Export
MetricLakewood-Amedex BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.45M$4.01B$7.25B$12.91B
Dividend YieldN/A3.60%2.54%9.13%
P/E Ratio-0.4012.65273.2725.43
Price / SalesN/A1,344.31624.5595.06
Price / CashN/A45.0028.9235.62
Price / BookN/A16.3911.016.39
Net Income-$3.85M-$22.85M$3.49B$358.69M
7 Day Performance-31.88%1.47%1.25%1.31%
1 Month Performance-15.32%6.03%4.39%-0.12%
1 Year PerformanceN/A49.09%23.87%13.75%

Lakewood-Amedex Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABT
Lakewood-Amedex Biotherapeutics
0.7274 of 5 stars		$1.88
flat		N/AN/A$4.45MN/AN/A5
TPST
Tempest Therapeutics
0.8049 of 5 stars		$1.03
-1.9%		N/A-90.6%$17.37MN/AN/A20
BIVI
BioVie
0.774 of 5 stars		$2.00
-1.5%		N/A+14.9%$17.16MN/AN/A10
BCDA
BioCardia
4.0477 of 5 stars		$1.08
-0.9%		$25.00
+2,214.8%		-47.6%$16.50M$60KN/A40
APLT
Applied Therapeutics
1.3496 of 5 stars		$0.10
flat		$1.00
+870.9%		N/A$15.86M$1MN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 9/8/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
The Market Isn't Loyal to You
Central banks are buying and holding gold at record highs as part of their reserve diversification strategies,...
Preserve Gold | Sponsoredtc pixel